Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:REXN

Rexahn Pharmaceuticals (REXN) Stock Price, News & Analysis

Rexahn Pharmaceuticals logo

About Rexahn Pharmaceuticals Stock (NASDAQ:REXN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.81
$2.24
52-Week Range
N/A
Volume
2,579 shs
Average Volume
162,968 shs
Market Capitalization
$8.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Receive REXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rexahn Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REXN Stock News Headlines

Aurinia Pharmaceuticals Inc AUPH
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Rexahn: Holes Galore in Serdaxin Data
See More Headlines

REXN Stock Analysis - Frequently Asked Questions

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.34.

Rexahn Pharmaceuticals's stock reverse split on Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 11th 2019. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SELLAS Life Sciences Group (SLS), Dynavax Technologies (DVAX), Imunon (CLSN) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

Last Earnings
8/07/2019
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:REXN
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.48 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$8.11 million
Optionable
Optionable
Beta
0.98
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:REXN) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners